Effective Holographic Theories for low-temperature condensed matter systems

The IR dynamics of effective holographic theories capturing the interplay between charge density and the leading relevant scalar operator at strong coupling are analyzed. Such theories are parameterized by two real exponents $(\gamma,\delta)$ that control the IR dynamics. By studying the thermodynamics, spectra and conductivities of several classes of charged dilatonic black hole solutions that include the charge density back reaction fully, the landscape of such theories in view of condensed matter applications is characterized. Several regions of the $(\gamma,\delta)$ plane can be excluded as the extremal solutions have unacceptable singularities. The classical solutions have generically zero entropy at zero temperature, except when $\gamma=\delta$ where the entropy at extremality is finite. The general scaling of DC resistivity with temperature at low temperature, and AC conductivity at low frequency and temperature across the whole $(\gamma,\delta)$ plane, is found. There is a codimension-one region where the DC resistivity is linear in the temperature. For massive carriers, it is shown that when the scalar operator is not the dilaton, the DC resistivity scales as the heat capacity (and entropy) for planar (3d) systems. Regions are identified where the theory at finite density is a Mott-like insulator at T=0. We also find that at low enough temperatures the entropy due to the charge carriers is generically larger than at zero charge density.Comment: (v3): Added discussion on the UV completion of the solutions, and on extremal spectra in the charged case. Expanded discusion on insulating extremal solutions. Many other refinements and corrections. 126 pages. 48 figure

Ga-Modified (Si-Ca-P) Sol-Gel Glasses: Possible Relationships Between Surface Chemical Properties and Bioactivity

In vitro bioactivity features of a Ga-modified sol gel Si-Ca-P glass(SGGa) were investigated, in comparison with a plain ternary Si-Ca-P system(SG). Reaction/dissolution of the glass at increasing soaking times in simulatedbody fluids (SBF) and the consequent growth of an apatite-like layer, monitoringbioactivity, were studied by employing a variety of chemical and physical techniques.The growth of a crystalline apatitic layer at the Ga-modified-glass/SBFinterface is severely delayed with respect to the Ga-free glass, and the reasons for ithave been looked for in the dramatic changes induced, at the glass/SBF interface, bythe presence of the Ga2O3 component. In situ Fourier transform infraredspectroscopy allowed to describe the nature/structure of surface terminations forthe two glasses and to reveal/quantify the acidic strength of different Ga speciesexposed at the SGGa glass surface. 2,6-Dimethylpyridine and carbon monoxidewere employed as molecular probes to reveal Brønsted and Lewis acidity. At thesurface of the Ga-modified glass, both Brønsted and strong Lewis acidic sites are present. The enhanced surface acitiy of SGGa glass,with respect to the plain glass SG, has been proposed to be responsible for the slower glass dissolution in SBF and for the delayeddeposition/crystallization of an apatite-like layer at the glass/SBF interface

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial

Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA. Methods: Between Dec 19, 2006, and April 2, 2010, patients were enrolled in the ARISTOTLE trial at 1034 clinical sites in 39 countries. 18 201 patients with AF or atrial flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target international normalised ratio 2·0-3·0). The median duration of follow-up was 1·8 years (IQR 1·4-2·3). The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat. The primary safety outcome was major bleeding in the on-treatment population. All participants, investigators, and sponsors were masked to treatment assignments. In this subgroup analysis, we estimated event rates and used Cox models to compare outcomes in patients with and without previous stroke or TIA. The ARISTOTLE trial is registered with ClinicalTrials.gov, number NTC00412984. Findings: Of the trial population, 3436 (19%) had a previous stroke or TIA. In the subgroup of patients with previous stroke or TIA, the rate of stroke or systemic embolism was 2·46 per 100 patient-years of follow-up in the apixaban group and 3·24 in the warfarin group (hazard ratio [HR] 0·76, 95% CI 0·56 to 1·03); in the subgroup of patients without previous stroke or TIA, the rate of stroke or systemic embolism was 1·01 per 100 patient-years of follow-up with apixaban and 1·23 with warfarin (HR 0·82, 95% CI 0·65 to 1·03; p for interaction=0·71). The absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0·77 per 100 patient-years of follow-up (95% CI -0·08 to 1·63) in patients with and 0·22 (-0·03 to 0·47) in those without previous stroke or TIA. The difference in major bleeding with apixaban compared with warfarin was 1·07 per 100 patient-years (95% CI 0·09-2·04) in patients with and 0·93 (0·54-1·32) in those without previous stroke or TIA. Interpretation: The effects of apixaban versus warfarin were consistent in patients with AF with and without previous stroke or TIA. Owing to the higher risk of these outcomes in patients with previous stroke or TIA, the absolute benefits of apixaban might be greater in this population. Funding: Bristol-Myers Squibb and Pfizer. © 2012 Elsevier Ltd

Apixaban versus warfarin in patients with atrial fibrillation

BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. RESULTS: The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42). CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Copyright © 2011 Massachusetts Medical Society. All rights reserved